# EDGAR Filing Document

**Accession Number:** 0001832928
**File Stem:** 0001832928-25-000013
**Filing Date:** 2025-6
**Character Count:** 15352
**Document Hash:** c20769a6750aa10e69103394567b2d17
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001832928-25-000013.hdr.sgml**: 20250613

**ACCESSION NUMBER**: 0001832928-25-000013

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 7

**CONFORMED PERIOD OF REPORT**: 20250612

**FILED AS OF DATE**: 20250613

**DATE AS OF CHANGE**: 20250612

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cresco Labs Inc.
- **CENTRAL INDEX KEY:** 0001832928
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981505364
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-56241
- **FILM NUMBER:** 251044427

**BUSINESS ADDRESS:**
- **STREET 1:** 600 W. FULTON STREET, SUITE 800
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60661
- **BUSINESS PHONE:** (312) 929-0993

**MAIL ADDRESS:**
- **STREET 1:** 600 W. FULTON STREET, SUITE 800
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60661

**UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION <br>Washington, D.C. 20549**

**FORM 6-K**

**Report of Foreign Private Issuer<br>Pursuant to Rule 13a-16 or 15d-16**

**Under the Securities Exchange Act of 1934**

**For the month of June, 2025**

**000-56241**

**(Commission File Number)**

**Cresco Labs Inc.**<br> (Exact name of Registrant as specified in its charter)

**600 W. Fulton Street, Suite 800 <br>Chicago, IL 60661**<br>(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☐&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F ☒

------

**INFORMATION CONTAINED IN THIS FORM 6-K REPORT**

On June 12, 2025, Cresco Labs Inc. (the "**Company**") filed a notice of change of auditor and related documents with Canadian securities regulatory authorities and issued a news release regarding the auditor change. Copies of these documents are furnished as Exhibits to this Report on Form 6-K.

This Report on Form 6-K and the exhibits attached hereto are hereby incorporated by reference into the Company's effective registration statements (including any prospectuses forming a part of such registration statements) on file with the U.S. Securities and Exchange Commission (the "**SEC**") and are to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

------

---

| | |
|:---|:---|
| **EXHIBIT INDEX** | **EXHIBIT INDEX** |
| **Exhibit No.** | **Description** |
| <u>[99.1](exhibit991-noticeofchangeo.htm)</u> | Notice of Change of Auditor |
| <u>[99.2](predecessorauditorletter.htm)</u> | Letter from Former Auditor |
| <u>[99.3](crescolabs-bakertillysuc.htm)</u> | Letter from Successor Auditor |
| <u>[99.4](auditorchangepr_2040-clean.htm)</u> | News Release dated June 12, 2025 |

---

---

| | | |
|:---|:---|:---|
| **SIGNATURES** | **SIGNATURES** | **SIGNATURES** |
| Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. | Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. | Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. |
|  | **CRESCO LABS INC.** | **CRESCO LABS INC.** |
| Date: June 12, 2025 | By: | /s/ Charles Bachtell |
|  |  | Charles Bachtell |
|  |  | Chief Executive Officer |

---

## Exhibit 99.1

Exhibit 99.1

**CRESCO LABS INC.**

**NOTICE OF CHANGE OF AUDITOR**

**(National Instrument 51-102)**

---

| | |
|:---|:---|
| **TO:** | **Baker Tilly US, LLP** |
| **AND TO:** | **Marcum LLP** |
| **AND TO:** | **British Columbia Securities Commission** |
| | **Alberta Securities Commission** |
| | **Financial and Consumer Affairs Authority of Saskatchewan** |
| | **The Manitoba Securities Commission** |
| | **Ontario Securities Commission** |
| | **Autorité Des Marchés Financiers** |
| | **New Brunswick Financial and Consumer Services Commission** |
| | **Nova Scotia Securities Commission** |
| | **Prince Edward Island Office of the Superintendent of Securities** |
| | **Superintendent of Securities (Newfoundland and Labrador)** |

---

**RE:&nbsp;&nbsp;&nbsp;&nbsp;Notice Regarding Change of Auditor Pursuant to Section 4.11 of National Instrument 51-102 – *Continuous Disclosure Obligations* ("NI 51-102")**<br>

Notice is hereby given of a change of the auditor of Cresco Labs Inc. (the "**Corporation**") pursuant to section 4.11 of NI 51-102. Take notice that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Marcum LLP ("**Marcum**") was terminated as auditor of the Corporation effective June 9, 2025 ("**End Date**"), and Baker Tilly US, LLP ("**Baker Tilly**") has been appointed as successor auditor effective June 12, 2025;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)the termination of Marcum and the appointment of Baker Tilly as the Corporation's auditor, have been recommended and approved by the Corporation's audit committee and board of directors, respectively;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)there were no modified opinions expressed in Marcum's reports on any of the financial statements of the Corporation which it audited, namely the year ending December 31, 2024, or during the subsequent interim period through and including the End Date;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)there are no reportable events (as defined in section 4.11 of NI 51-102); and,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)the Corporation has requested that Marcum and Baker Tilly each furnish a letter addressed to the securities administrators in each province in which the Corporation is a reporting issuer stating whether or not they agree with the information contained in this notice. A copy of each such letter to the securities administrators will be filed with this notice.

DATED this 12th day of June, 2025.

---

| |
|:---|
| **CRESCO LABS INC.** |
| *"Charles Bachtell"* |
| Charles Bachtell |
| Chief Executive Officer |

---

## Exhibit 99.2

![](predecessorauditorletter001.jpg)

Marcum llp / 730 Third Avenue / 11th Floor / New York, NY 10017 / Phone 212.485.5500 / marcumllp.com June 12, 2025 British Columbia Securities Commission Alberta Securities Commission Financial and Consumer Affairs Authority of Saskatchewan The Manitoba Securities Commission Ontario Securities Commission Autorité Des Marchés Financiers New Brunswick Financial and Consumer Services Commission Nova Scotia Securities Commission Prince Edward Island Office of the Superintendent of Securities Superintendent of Securities (Newfoundland and Labrador) Re: Cresco Labs Inc. (the "Company") Dear Sir/Madam: As required by National Instrument 51-102, we have reviewed the information contained in the Company's Notice of Change in Auditors dated June 12, 2025. Based on our knowledge of such information at this date, we agree with the statements set out in the Notice that pertains to our firm. Very truly yours, /gcp S:\BUSINESS\Word_Processing\Common\Finalized\Cresco Labs\2025\Letters\208761 Change of Accountants Letter 06.12.25.docx Exhibit 99.2

------

## Exhibit 99.3

![](crescolabs-bakertillysuc001.jpg)

Baker Tilly Advisory Group, LP and Baker Tilly US, LLP, trading as Baker Tilly, are members of the global network of Baker Tilly International Ltd., the members of which are separate and independent legal entities. Baker Tilly US, LLP is a licensed CPA firm that provides assurance services to its clients. Baker Tilly Advisory Group, LP and its subsidiary entities provide tax and consulting services to their clients and are not licensed CPA firms. Baker Tilly US, LLP 205 N Michigan Ave, 28th Fl Chicago, IL 60601-5927 United States of America T: +1 (312) 729 8000 F: +1 (312) 729 8199 bakertilly.com June 12, 2025 British Columbia Securities Commission Alberta Securities Commission Financial and Consumer Affairs Authority of Saskatchewan The Manitoba Securities Commission Ontario Securities Commission Autorité Des Marchés Financiers New Brunswick Financial and Consumer Services Commission Nova Scotia Securities Commission Prince Edward Island Office of the Superintendent of Securities Superintendent of Securities (Newfoundland and Labrador) Dear Sirs/Mesdames: Re: Cresco Labs Inc. (the "Company") – Change of Auditor Pursuant to National Instrument 51-102 – Continuous Disclosure Obligations, we have reviewed the information contained in the Notice of Change of Auditor of the Company dated June 12, 2025 (the "Notice") and, based on our knowledge of such information at this time, we agree with the statements made in the Notice. Yours very truly, Baker Tilly US, LLP Chicago, IL Exhibit 99.3

------

## Exhibit 99.4

Cresco Labs Exhibit 99.4 <br>

*Page 1 of 2*

**Cresco Labs Announces Change of Auditor**

**CHICAGO – June 12, 2025 –** Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) ("**Cresco Labs**" or the "**Company**"), today announced it has changed its auditor from Marcum LLP ("**Marcum**") to Baker Tilly US, LLP ("**Baker Tilly**"). Cresco will seek shareholder ratification of Baker Tilly's appointment at the next annual meeting of shareholders.

Marcum was terminated as the Company's auditor effective June 9, 2025, and Baker Tilly has been appointed as successor auditor effective June 12, 2025. The change in auditor was recommended and approved by the Company's audit committee and board of directors (the "**Board**"), respectively.

"After an extensive three-month selection process, we are thrilled to appoint Baker Tilly as our independent auditor," said Sharon Schuler, CFO. "With the approval of our Board of Directors, Baker Tilly will begin their engagement with the review of our Q2 2025 financial statements. We are confident in their expertise and look forward to a collaborative partnership as we continue to maintain the highest standards of financial transparency and regulatory compliance."

There were no modified opinions in Marcum's audit reports for any financial period during which Marcum was the Company's auditor. There are no "reportable events" (as such term is defined in National Instrument 51-102 Continuous Disclosure Obligations ("NI 51-102")) between the Company and Marcum.

In accordance with NI 51-102, the change of auditor notice, together with the required letters from the Marcum and Baker Tilly, have been reviewed and approved, as applicable, by the Board and have been filed on SEDAR+.

**About Cresco Labs Inc.**

Cresco Labs' mission is to normalize and professionalize the cannabis industry through a CPG approach to building national brands and a customer-focused retail experience, while acting as a steward for the industry on legislative and regulatory-focused initiatives. As a leader in cultivation, production, and branded product distribution, the Company is leveraging its scale and agility to grow its portfolio of brands that include Cresco, High Supply, FloraCal, Good News, Wonder Wellness Co., Mindy's, and Remedi, on a national level. The Company also operates highly productive dispensaries nationally under the Sunnyside brand that focus on building patient and consumer trust and delivering ongoing education and convenience in a wonderfully traditional retail experience. Through year-round policy, community outreach and SEED initiative efforts, Cresco Labs embraces the responsibility to support communities through authentic engagement, economic opportunity, investment, workforce development, and legislative initiatives designed to create the most responsible, respectable and robust cannabis industry possible. Learn more about Cresco Labs' journey by visiting <u>www.crescolabs.com</u> or following the Company on <u>Facebook</u>, <u>X</u> or <u>LinkedIn</u>.

------

Cresco Labs <br>

*Page 2 of 2*

**Forward-Looking Statements**

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995 (collectively, "forward-looking statements"). Such forward-looking statements are not representative of historical facts or information or current condition but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company's control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as, 'may,' 'will,' 'should,' 'could,' 'would,' 'expects,' 'plans,' 'anticipates,' 'believes,' 'estimates,' 'projects,' 'predicts,' 'potential,' or 'continue,' or the negative of those forms or other comparable terms. The Company's forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to those risks discussed under "Risk Factors" in the Company's Annual Information Form for the year ended December 31, 2024, filed on SEDAR+ and EDGAR, other documents filed by the Company with Canadian securities regulatory authorities; and other factors, many of which are beyond the control of the Company. Readers are cautioned that the foregoing list of factors is not exhaustive. Because of these uncertainties, you should not place undue reliance on the Company's forward-looking statements. No assurances are given as to the future trading price or trading volumes of Cresco Labs' shares, nor as to the Company's financial performance in future financial periods. The Company does not intend to update any of these factors or to publicly announce the result of any revisions to any of the Company's forward-looking statements contained herein, whether as a result of new information, any future event, or otherwise. Except as otherwise indicated, this press release speaks as of the date hereof. The distribution of this press release does not imply that there has been no change in the affairs of the Company after the date hereof or create any duty or commitment to update or supplement any information provided in this press release or otherwise.

**Contacts**

**Media**

<u>Press@crescolabs.com</u>

**Investors**

TJ Cole, Cresco Labs

SVP, Corporate Development & Investor Relations

<u>investors@crescolabs.com</u>

*For general Cresco Labs inquiries:*

312-929-0993

<u>info@crescolabs.com</u>

<br>